You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Proteolytic Imaging of Remodeling Myocardium

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Developing novel RPPA for the detection of metastatic prostate cancer

    SBC: Tymora Analytical Operations, LLC            Topic: 102

    PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Screening the Ribosome for New Target Sites

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Optimized AAV Serotype Vectors for Human Gene Therapy

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Dental Adhesives to Prevent Recurrent Caries

    SBC: CuRE Innovations, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government